-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 19, researcher Li Huabing's team from Shanghai Institute of Immunology, Shanghai Jiaotong University School of Medicine and Prof.
Immunotherapy targeting PD1/PD-L1 has achieved remarkable results in the treatment of various tumors, creating a new era of tumor immunotherapy.
The previous work of the research group has screened 700 RBPs through CRISPR/Cas9 technology, and identified that the m6A methyltransferase METTL3 positively regulates the expression of TNF-α and other inflammatory factors in macrophages to inhibit tumor growth 5
In this study, the research team screened 1467 RBPs by CRISPR/Cas9 technology and found that knocking out the density-regulated translation reinitiation factor DENR could significantly reduce the expression of PD-L1 in various cells
Figure 1.
Dr.
